wavebreakmedia / Shutterstock.com
The US National Institutes of Health (NIH) has decided not to exercise its “march in-rights” for the Xtandi (enzalutamide) prostate drug, which is marketed by Astellas Pharma, despite calls from politicians to license the drug in a bid to lower its price.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
National Institutes of Health, Astellas Pharma, Xtandi, enzalutamide, Francis Collins, Bayh-Dole Act, patent, march-in rights, patent
